Skip to main content
Explore URMC

Nimish A. Mohile, M.D.

Contact Information

Phone Numbers

Appointment: (585) 275-5830

URMFGA member of the University of Rochester Medical Faculty Group

groupAn Accountable Health Partner

assignmentAccepting New Patients

Faculty Appointments

Patient Care Settings

Cancer, Neurology


Dr. Mohile completed his residency training at Northwestern University, followed by a fellowship in neuro-oncology at Memorial Sloan-Kettering Cancer Center. He is certified in Neurology and Neuro-oncology. In 2007, he joined the neurology department at the University of Rochester where he built and fostered the neuro-oncology division and multi-disciplinary brain tumor program. His mission is to teach, elevate clinical care and perform research that extends and improves the lives of patients with brain tumors.

Dr. Mohile sees patients with primary and metastatic brain tumors and is involved in administering chemotherapy, treating seizures and managing side effects of brain tumors and brain tumor therapy. In addition, he does consultations on patients with neurologic complications of cancer or cancer treatments.

Professional Background

Nimish Mohile, MD, MS, FAAN is an Associate Professor of Neurology and Oncology at the University of Rochester and the Ann Aresty Camhi Professor of Neurology. He serves as the Associate Chair for Career Development and Leadership, Neuro-oncology Division Chief and Leader of the Neuro-oncology service line. He is a UCNS fellowship program director, serves on the UCNS Certification committee, chairs the American Society of Clinical Oncology Glioma Guidelines Panel and is currently the Vice-chair of the AAN section for Neuro-oncology.

As an Associate Chair for Career Development and Leadership, he has spearheaded innovative programs that emphasize personal values, identity and reflective work in the professional development of faculty, administrative staff, advanced practice providers and residents. He also directs departmental leadership programs for residents and faculty to develop leadership skills, implement change and develop resilient teams.

Dr. Mohile aspires to help organizations transform into multicultural, antiracist and equitable entities. He is an advocate for incorporating principles of inclusion, diversity, equity, antiracism and social justice into the profession of neurology. He serves as a diversity officer in the Department of Neurology at the University of Rochester, where he also chairs the Antiracism working group. He currently co-chairs the AAN Diversity Officer’s Group, is a member of the EDI Joint Coordinating Council and was recently appointed to the AAN Special Commission for Racism, Inequity and Social Justice.


His research focuses on developing and testing therapeutic and supportive care interventions to improve and extend the lives of patients with malignant gliomas. He has authored over 50 peer-reviewed publications. He is currently the principal investigator of several industry-sponsored, investigator-initiated and NCI- funded clinical trials. He has developed a body of work that explores the burdens experienced by patients wtih brain tumors and caregivers, related to hospitalizations, seizures, decision-making and end of life care.



  • Neurology - American Board of Psychiatry and Neurology


MD | St. George's University School of Medicine

Post-doctoral Training & Residency

07/01/2005 - 06/30/2007
Fellowship in at Memorial Sloan-Kettering Cancer Center

07/01/2004 - 06/30/2005
Fellowship in Neurophysiology at Northwestern University Medical School

07/01/2001 - 06/30/2004
Residency in Neurology at Northwestern University Medical School

07/01/2000 - 06/30/2001
Internship in Internal Medicine at Norwalk Hospital

VIEW ALL expand_more


A. B. Baker Teacher Recognition Award
Sponsor: American Academy of Neurology

SWOG Travel Award Recipient
Sponsor: Southwest Oncology Group

Neurology Faculty Teaching Award
Sponsor: University of Rochester
Location: Rochester, NY

American Neurological Association Junior Academic Scholarship Award

American Society of Clinical Oncology Foundation Merit Award
Sponsor: American Society of Clinical Oncology Foundation

Graduate Medical Education Award for excellence in teaching medical students

AAN Resident Annual Meeting Scholarship
Sponsor: American Academy of Neurology

1996 - 2000
Dean's List
Sponsor: St George's University
Location: Grenada, WI

Dean's List
Sponsor: Duke University
Location: Durham, NC

VIEW ALL expand_more

Clinical Trials

A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy,A Randomized, Multicenter, Phase 2 Study of DSP-7888 Dosing Emulsion in Combination with Bevacizumab versus Bevacizumab Alone in Patients with Recurrent or Progressive Glioblastoma following Initial Therapy

Lead Researcher: Nimish A Mohile

This is a dose-escalation study of DSP-7888 Dosing Emulsion administered to adult patients with advanced malignancies. Patients will be administered escalating doses of DSP-7888 Dosing Emulsion intradermally (between the skin layers) or subcutaneously (under the skin) in accordance with the following regimen: once weekly for four weeks during the Induction Phase, once every 7 to 14 days for 6 weeks during the Consolidation Phase, and once every 14 to 28 days until a discontinuation criterion is met during the Maintenance Phase. Once the highest dose with acceptable toxicity is determined from either the intradermal or subcutaneous group, an additional 40 patients may be enrolled as an expansion cohort at this dose and route of administration to confirm safety and tolerability. Separate from the dose-ascending cohort and expansion cohort described previously, and once the intradermal dose-ascending cohort is completed, up to 20 myelodysplastic syndrome (MDS) patients who are resistant to treatment with hypomethylating agents (HMAs) will be enrolled into an MDS expansion cohort. Of these 20 MDS patients, one-half will receive DSP-7888 at 10.5 mg according to the modified schedule employed in Phase 1 (every week for 4 weeks, every 2 weeks until Week 24, and then every 4 weeks [Named MDS Cohort 1]). The other half of the MDS patients will receive DSP-7888 at 10.5 mg in an alternative dosing schedule where DSP-7888 is administered every 2 weeks until Week 24, after which it will be administered every 4 weeks (Named MDS Cohort 2).

View Study Details


Journal Articles

Xu H, Kadambi S, Mohile SG, Yang S, Kehoe LA, Wells M, Culakova E, Kamen C, Obrecht S, Mohamed M, Gilmore NJ, Magnuson A, Grossman VA, Hopkins JO, Geer J, Berenberg J, Mustian K, Cupertino A, Mohile N, Loh KP. "Caregiving burden of informal caregivers of older adults with advanced cancer: The effects of rurality and education." Journal of geriatric oncology.. 2021 Apr 12; Epub 2021 Apr 12.

Mohile NA, Spector AR, Ebong IM, Flippen C, Gutierrez C, Leacock RO, Marulanda-Londoño E, Mejia NI, Thomas R, Hamilton RH. "Developing the Neurology Diversity Officer: A Roadmap for Academic Neurology Departments." Neurology.. 2021 Jan 5; Epub 2021 Jan 05.

Warren KT, Liu L, Liu Y, Strawderman MS, Hussain AH, Ma HM, Milano MT, Mohile NA, Walter KA. "Time to treatment initiation and outcomes in high-grade glioma patients in rehabilitation: a retrospective cohort study." CNS oncology.. 2020 Oct 28; :CNS64. Epub 2020 Oct 28.

Books & Chapters

Chapter Title: Principles of Chemotherapy
Book Title: Brain Tumors: Practical Guide to Diagnosis and Treatment
Author List: Abrey LE and Mohile NA
Edited By: Baehring J, Piepmeier J
Published By: Informa Health Care, USA 2007 in New York

Chapter Title: Chemotherapy of Neuronal Tumors
Book Title: Handbook of Brain Tumor Chemotherapy
Author List: Mohile, N.A.; Raizer, J.J.
Edited By: Newton, H.B.
Published By: Elsevier 2006 in Amsterdam: Boston